International normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXELIGIBILITY CRITERIA FOR RANDOMIZATION (STEP 1): International normalized ratio (INR) =< 3 (to be done/tested only for subjects on warfarin)Xx_NEWLINE_xXPatients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic rangeXx_NEWLINE_xXPatients on low molecular weight heparin or Coumadin (with a stable international normalized ratio [INR]) are eligibleXx_NEWLINE_xXSubjects taking warfarin should be monitored regularly for changes in prothrombin time or international normalized ratio (INR)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXObtained within 14 days prior to treatment start: International normalized ratio (INR) =< 1.5Xx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5Xx_NEWLINE_xXWithin 10 days of treatment initiation: Institutional normalized ratio (INR) =< 1.5 X institutional upper limit of normal (IULN)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.1 x institutional upper limit of normalXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 times ULN; subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)Xx_NEWLINE_xXEvidence of bleeding diathesis or significant coagulopathy (in the absence of therapeutic anticoagulation); (to be eligible, prothrombin time/international normalized ratio [PT INR] should be < 1.4 for patients not on warfarin)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2Xx_NEWLINE_xXInternational normalized ratio of < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR)/PTT =< 2 times normal; timeline: within 3 weeks prior to enrollmentXx_NEWLINE_xXBlood coagulation parameters: international normalized ration (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) ? 1.5 × ULN (? 2.5 × ULN if on anticoagulants)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXAdequate coagulation tests: international normalized ratio ?1.5Xx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) = 1.7Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 unless on direct thrombin inhibitor at time of study entryXx_NEWLINE_xXINR > 1.3Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXINR < 1.3 (or < 3 on anticoagulants)Xx_NEWLINE_xXCoagulation: International normalized ratio (INR) ?1.2 within 28 days of starting study.Xx_NEWLINE_xXProthrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)Xx_NEWLINE_xXInternational normalized ratio (INR) ?1.5;Xx_NEWLINE_xXAdequate blood coagulation function defined by International Normalized Ratio (INR) ?1.5 (except for participants on warfarin therapy where INR must be ?3.0 prior to randomization)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXObtained =< 2 weeks prior to registration: International normalized ratio (INR) =< 1.5 ULNXx_NEWLINE_xXProthrombin time (PT)-international normalized ratio (INR) =< 1.5 x institutional ULN (for participants on anticoagulation therapy, =< 1.5 x their baseline value)Xx_NEWLINE_xXInternational normalized ratio =< 1.5Xx_NEWLINE_xXINR < 1.5 × ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational Normalized Ratio (INR) for coagulation above upper normal rangeXx_NEWLINE_xXInternational normalized ratio (INR) ? 2 × ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) INR ?1.5 × institutional ULN or PT ?5 seconds above institutional ULNXx_NEWLINE_xXInternational Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).Xx_NEWLINE_xXINR ?1.5× ULNXx_NEWLINE_xXInternational normalized ratio/prothrombin time ? 1.5 x upper limit or normalXx_NEWLINE_xXTransaminases ? 2 times above the upper limits of the institutional normal, - INR<2 (international normalized ratio) if off of anticoagulation. Patients on anticoagulation therapy with an INR>2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhage and if the site to be injected is not located in the oropharynx or another area where achieving homeostasis would be complicated by local anatomy.Xx_NEWLINE_xXProthrombin time international normalized ratio (INR) =< 2Xx_NEWLINE_xXMust have an international normalized ratio (INR) < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational Normalized Ratio (INR) > 1.5Xx_NEWLINE_xXNormal coagulation defined as normal International Normalized Ratio (INR) or per institutional guidelines.Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.7Xx_NEWLINE_xXInternational normalized ratio (INR) < 2.0.Xx_NEWLINE_xXProthrombin (PT) - international normalized ratio (INR) < 1.5Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULN, obtained =< 14 days prior to registrationXx_NEWLINE_xXInternational normalized ratio (INR) less than 1. 5 X ULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5.Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3Xx_NEWLINE_xXInternational normal ratio (INR) < 1.3 or ? institutional ULN (or ? 3.0 if on therapeutic anticoagulation)Xx_NEWLINE_xXPatients on therapeutic anti-coagulation are eligible if there is no bleeding and they are on a stable dose of anti-coagulation therapy (e.g., on coumadin with an international normalized ratio [INR] of 2 to 3) for at least 7 days before registration (prior to the start of therapy)Xx_NEWLINE_xXInternational normalized ratio > 1.5Xx_NEWLINE_xXPatients who have an international normalized ratio (INR) or platelet count which are not correctable to < 1.8 and > 35,000 respectivelyXx_NEWLINE_xXINR ? 1.5Xx_NEWLINE_xXObtained with 21 days of registration: international normalized ratio =< 2.3Xx_NEWLINE_xXINR < 1.5 × ULNXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 x institutional upper limit of normal (or an in-range INR, usually between 2 and 3 if a patient is on a stable dose of therapeutic warfarin)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) for patients not receiving therapeutic anticoagulation (unless dysfunction is secondary to lymphoma involvement)Xx_NEWLINE_xXInternational normalized ratio (INR) < 2, at the time of enrollment; subjects on anticoagulation (such as coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigatorXx_NEWLINE_xXInternational normalized ratio (INR) from 0.8 to 1.2Xx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 X ULNXx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 (except for patients who are on full-dose warfarin)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULNXx_NEWLINE_xXINR ? 1.5 x ULN;Xx_NEWLINE_xX(For both cohorts A and B): International normalized ratio (INR) =< 2Xx_NEWLINE_xXPT (Prothrombin time) and/or international normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 obtained < 4 weeks prior to starting treatmentXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational Normalized Ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin) (obtained within 28 days prior to first study treatment)Xx_NEWLINE_xXIf subject is receiving Coumadin (warfarin), a stable international normalization ratio (INR) of 2-3 is required.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXProthrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ration (INR) within 1.25 x ULN institutional limits, except where a lupus anti-coagulant has been confirmedXx_NEWLINE_xXObtained =< 14 days prior to registration: Prothrombin time (PT)/international normalized ratio (INR) =< 1.5 X ULNXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5Xx_NEWLINE_xXProthrombin time/international normalized ratio (PT INR) < 1.4Xx_NEWLINE_xXInternational normalization ratio (INR) < 1.5 times ULN, or if on warfarin, can safely transition off for biopsyXx_NEWLINE_xXInternational normalization ratio (INR) < 1.5 times ULN, or if on warfarin, can safely transition off for biopsyXx_NEWLINE_xXINR ?1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.7Xx_NEWLINE_xXObtained within 14 days prior to registration; international normalized ratio (INR) ? 2Xx_NEWLINE_xXINR > 2Xx_NEWLINE_xXProthrombin time (PT) and international normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXCompleted within 60 days of surgery: International normalized ratio INR ? 1.5 in patients not utilizing systemic anticoagulation as part of their medical regimenXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above control (within 14 days prior to registration)\r\n* NOTE: Abnormal PT/INR may be considered, with documented principal investigator (PI) approval, if it is due to the use of anticoagulants; for such patients, a normal PT/INR must be available from before the start of anticoagulation treatment\r\n* NOTE: Performed at time of screening angiogram; can be outside 14 days if applicableXx_NEWLINE_xXProthrombin time with international normalized ratio (INR) =< ULN for the laboratoryXx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0 or correctable to 2.0 with vitamin K therapyXx_NEWLINE_xXInternational normalized ratio (INR) > 1.5 INRXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) < IULN or prothrombin time (PT) < IULNXx_NEWLINE_xXInternational normalized ratio (INR) >= 1.7Xx_NEWLINE_xXInternational normalized ratio (INR) < 2 if off of anti-coagulation; patients on anti-coagulation therapy with an INR > 2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhageXx_NEWLINE_xXObtained =< 14 days prior to registration: International normalized ratio (INR) =< 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) =< IULN or prothrombin time (PT) =< IULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXProthrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarinXx_NEWLINE_xXTherapeutic anticoagulation with international normalized ratio (INR) modifying drug of or use of antiplatelet therapy (with the exception of low dose aspirin < 325mg/d)Xx_NEWLINE_xXProthrombin time (PT)/international normalization ratio (INR) < 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 unless on warfarin in which case INR < 3.0 is acceptableXx_NEWLINE_xXInternational normalized ration (INR) =< 1.5Xx_NEWLINE_xXThe patient must have adequate coagulation function as defined by international normalized ratio (INR) =< 1.5 andXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXINR >= 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0Xx_NEWLINE_xXWithin 3 months of registration: International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x institutional ULNXx_NEWLINE_xXProthrombin time or international normalized ratio (INR) =< 1.5 X upper limit of normal (ULN)Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) < 1.7 unless using warfarin for therapeutic anti-coagulationXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5, except for subjects receiving warfarin therapy; for subjects who are receiving warfarin for prophylaxis or treatment of thrombosis, INR values should be carefully monitored while patients are on studyXx_NEWLINE_xXInternational normalized ratio (INR) is =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) from 0.8 to 1.2Xx_NEWLINE_xXProthrombin time (PT) and international normalized ratio (INR) < 1.2 x ULNXx_NEWLINE_xXCoagulopathy international normalized ratio (INR) > 1.5Xx_NEWLINE_xXKnown, existing uncontrolled coagulopathy, international normalized ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXKnown coagulopathy/thrombocytopenia (international normalized ratio [INR] > 1.5, platelets < 75)Xx_NEWLINE_xXInternational normalized ratio (INR) < 2.0Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN (except for patients on anticoagulation)Xx_NEWLINE_xXInternational normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinnersXx_NEWLINE_xXInternational normalized ratio (INR) < 1.3Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN)Xx_NEWLINE_xX“International normalized ratio” or INR must be =< 1.5Xx_NEWLINE_xXPatients on anticoagulant therapy with unstable dose of warfarin and/or having an out-of- therapeutic range international normalized ratio (INR) (> 3) within the 4 weeks prior to drug administrationXx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) < 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.8Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN unless the patient is receiving anticoagulant therapyXx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) value greater than 1.5Xx_NEWLINE_xXAn international normalized ratio (INR) =< 1.5 (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) < 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 2Xx_NEWLINE_xXInternational normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinnersXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.2 x ULNXx_NEWLINE_xXAll patients should have normal coagulation, with international normalized ratio (INR) < 1.3 and able to withhold anti-coagulation medications a minimum of 24 hours prior to radiosurgery (or until INR normalizes), on the day of treatment and 24 hours after radiosurgery has concluded; those patients getting WBRT may continue these medicationsXx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN); subjects receiving anticoagulation therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) < 2; subjects on anticoagulant (such as coumadin) must have an international normalized ratio (INR) < 5Xx_NEWLINE_xXPatients receiving anti-coagulation treatment with an agent such as warfarin or heparin may be allowed to participate; for patients on warfarin, the international normalized ratio (INR) should be measured prior to initiation of sorafenib and monitored at least weekly, or as defined by the local standard of care, until INR is stableXx_NEWLINE_xXInternational normalized ratio (INR) < 2.0Xx_NEWLINE_xXEvidence of a bleeding diathesis, coagulopathy or prothrombin time (PT) international normalized ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) must be =< 2.3Xx_NEWLINE_xXInternational normalized ratio (INR)/prothrombin time (PT) =< 1.5 obtained =< 14 days prior to registrationXx_NEWLINE_xXInternational Normalized Ratio (INR) or PT/aPTT <1.5 x ULN. For subjects receiving anticoagulation therapy, PT/aPTT and INR should not be greater than the recommended range for the intended use of the anticoagulantXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.7Xx_NEWLINE_xXAdequate coagulation: international normalised ratio (INR) ?1.5 for patients on anti-coagulation therapyXx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) during screening evaluationXx_NEWLINE_xXCoagulation: Prothrombin Time (PT) > 4 seconds more than the ULN or International Normalized Ratio (INR) > 1.7Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x ULN; NOTE: subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXPatients should have normal coagulation [International Normalized Ratio (INR) < 1.3] and be able to withhold anticoagulation/antiplatelet medications a minimum of 24 hours prior to radiosurgery treatment (or until INR normalizes), on the day of treatment and 24 hours after radiosurgery treatment has concluded.Xx_NEWLINE_xXInternational normalized ratio (INR) > 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULN within 14 days prior to randomization; for laboratories that do not report an ULN for the INR assay, use =< 1.5 as the value for the ULN; patients receiving therapeutic anti-coagulants are not eligibleXx_NEWLINE_xXPT/international normalized ratio (INR) ?ULN; aPTT ?ULN.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ration (INR) < 1.5Xx_NEWLINE_xXInternational normalization ratio (INR) or prothrombin time (PT) ? 1.5 xXx_NEWLINE_xXInternational normalized ratio (INR) ? 2 (If coagulopathy is related to disease, this criterion does not apply) within 14 days prior to registrationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 =< 14 days prior to registrationXx_NEWLINE_xXInternational normalized ratio or INR must be ? 1.5 unless on therapeutic blood thinners ? 2 weeksXx_NEWLINE_xXInternational normalized ratio =< 1.5 and activated prothrombin time =< 1.5 x ULN for patients not receiving anti?coagulation therapyXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.4Xx_NEWLINE_xXWithin 14 days prior to registration: International normalized ratio (INR) < 2.0Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) within normal limits (+/- 15%) or within therapeutic range if on warfarinXx_NEWLINE_xXInternational normalized ratio of prothrombin time (INR) within 28 days before randomization must be =< ULN for the lab; patients who are therapeutically treated with an agent such as warfarin may participate if they are on a stable dose and no underlying abnormality in coagulation parameters exists per medical historyXx_NEWLINE_xXPerformed within 14 days prior to study: International normalized ratio (INR) < 2 if off of anticoagulation; patients on anticoagulation therapy with an INR > 2 may be enrolled at the discretion of the investigator if they have not had any episodes of severe hemorrhageXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXPatients with prothrombin time (PT) and/or international normalized ratio (INR) higher than or equal to 1.5 time upper limit of normal, unless patients have lupus anticoagulant in which case they are eligible if cleared by hematologyXx_NEWLINE_xXARM A: obtained =< 14 days prior to registration: \r\n* International normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.4 unless receiving therapeutic doses of coumadinXx_NEWLINE_xXObtained within 30 days prior to registration: International normalized ratio (INR) or prothrombin time (PT) =< 2 x ULN (Note: use of vitamin K antagonist is not allowed)Xx_NEWLINE_xXCohort 2 (MTD) only: prothrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalization ratio (INR) =< 2.0 mg/dLXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) within institutional normal limitsXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) < 1.25 x ULN (Cohort II [MTD] only)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants)Xx_NEWLINE_xXINR > 2.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5; subjects on anticoagulant (such as Coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigatorXx_NEWLINE_xXInternational normalized ratio (INR): < 1.5 x institutional upper limit of normal OR < 3 if on warfarin or other anticoagulants; there should be no evidence of active bleeding while on anticoagulantsXx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXINR =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXWithin 14 days of subject registration: International normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio =< 1.3 (or =< 3 on anticoagulants)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULN or prothrombin time (PT) =< 1.5 x ULN seconds above control unless patient is currently receiving warfarin therapy for the treatment or prevention of venous thrombosisXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 X ULN (if not on anticoagulation)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 (or < 3 if on warfarin or other anticoagulants)Xx_NEWLINE_xXProthrombin time (PT), international normalized ratio (INR) less than 1.5 times the institutional upper limit of normalXx_NEWLINE_xXProthrombin time (PT), international normalized ratio (INR) =< 1.5 x institutional ULN unless patient is therapeutically anticoagulated; if on anticoagulants, PT/INR need to be within appropriate anticoagulation limits for the clinical indication; patients who are receiving anticoagulants may participate in the trial if their anticoagulation can be stopped safely for several days at the time of each biopsyXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) monitoring, < 1.5 x institutional upper limits of normalXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) must be =< 1.2 x the laboratory ULNXx_NEWLINE_xXProthrombin time (PT) within 2 seconds of the upper limit of normal (international normalized ratio [INR] =< 1.8)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio or INR must be < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x institutional ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0Xx_NEWLINE_xXAdequate coagulation defined as\r\n* International normalized ratio (INR)/prothrombin time (PT) =< 1.5 x upper limit of normalXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above control; if subjects are being anticoagulated they can participate if proof of no coagulation abnormality existed prior to use of anticoagulantsXx_NEWLINE_xXProthrombin time (PT) =< 26 seconds or international normalized ratio (INR) =< 2.5Xx_NEWLINE_xXInadequate liver or renal function; Intracranial bleeds or invasive malignancy over the previous 2 years - international normalized ratio (INR) laboratory values cannot be > 1.5 x upper limit of normal at study entry.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXPerformed within 14 days of patient registration: International normalized ration (INR) =< 1.5Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN) (if not receiving anticoagulation therapy)Xx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ? 1.5.Xx_NEWLINE_xXCoagulation: International Normalized Ratio (INR) ? 1.2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2, obtained =< 21 days prior to registrationXx_NEWLINE_xXINR < 2.0Xx_NEWLINE_xXCoagulation: International Normalized Ratio (INR) ? 1.2Xx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) less than or equal to 1.5.Xx_NEWLINE_xXProthrombin Time - International Normalized Ratio (PT-INR)Xx_NEWLINE_xXInternational Normalized Ratio (INR) or Prothrombin Time (PT) ?1.5 X ULNXx_NEWLINE_xXSubjects with coagulopathies, including thrombocytopenia with platelet count < 75,000, international normalized ratio (INR) > 1.5 and partial thromboplastin time > 50 secXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) > 2Xx_NEWLINE_xXInternational normalized ratio (INR) < or equal to 1.5; patients receiving anti-coagulation treatment with an agent such as warfarin or heparin MAY be allowed to participate; for patients on warfarin, the INR should be measured prior to initiation of sorafenib and monitored weekly, or as defined by the local standard of care, until INR is stableXx_NEWLINE_xXInternational normalized ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) within normal limits (UIHC)Xx_NEWLINE_xXAdequate blood coagulation function, defined as international normalized ratio (INR) less than or equal to 2.3Xx_NEWLINE_xXProthrombin time/international normalized ratio (PT INR) < 1.4 for patients not on warfarin confirmed by testing within 14 days prior to study registrationXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 x institutional ULNXx_NEWLINE_xXInternational normalized ratio (INR) must be < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.4 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2; factor 10A drawn if patient on anticoagulant EliquisXx_NEWLINE_xXInternational normalized ratio (INR) > 2 in the absence of anticoagulation therapyXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5.Xx_NEWLINE_xXProthrombin time international normalized ratio (INR) =< 2; ANDXx_NEWLINE_xXInternational normalized ratio (INR) > 2Xx_NEWLINE_xXSubjects requiring anticoagulation with warfarin or vitamin K antagonists are excluded from the ibrutinib arm; if previously on these drugs and switched, international normalized ratio (INR) must be normal for 7 days prior to enrollmentXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio > 1.7Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 times ULNXx_NEWLINE_xXInternational normalized ratio 1.5 × ULN or prothrombin time 5 seconds above ULN.Xx_NEWLINE_xXInternational normalized ratio (INR) < 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 x ULN for institution unless patient is on planned therapy with anticoagulants (i.e., warfarin) with higher target planned obtained =< 14 days prior to registration; in those cases, INR up to 3.5 is acceptableXx_NEWLINE_xXINR < 1.5 × ULNXx_NEWLINE_xXProthrombin time (PT) such that international normalized ratio (INR) is less than or equal to 1.3 x upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXinternational normalized ratio (INR) must be within normal limits of the local laboratory ranges.Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXAdequate prothrombin time/international normalized ratio (PT/INR) < 1.4 for patients not on warfarin confirmed by testing within 21 days prior to study registrationXx_NEWLINE_xXInternational normalized ratio (INR) < 2Xx_NEWLINE_xXPatients must have normal coagulation studies (prothrombin time [PT]/international normalized ratio [INR] < 1.5 times ULN) within 14 days prior to the initiation of study treatmentXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) < 1.5 times upper limit of normal within 14 days before enrollmentXx_NEWLINE_xXInternational normalized ratio (INR) less than or equal to 2Xx_NEWLINE_xXProthrombin time (PT) such that international normalized ratio (INR) is =< 1.5 times upper limit of normal (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)Xx_NEWLINE_xXAdequate blood clotting time with an international normalized ratio (INR) < 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) > 2Xx_NEWLINE_xXInternational Normalized Ratio (INR) less than 1.5 within 8 weeks prior to initial cryoablation procedure.Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN) (tested within 14 days prior to registration) \r\n* Subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 institutional ULN unless on warfarin therapy (investigator would need to determine if safe for participant to stop warfarin prior to biopsy)Xx_NEWLINE_xXInternational normalized ratio (INR) must be less than 1.5 in patients not on Coumadin therapyXx_NEWLINE_xXPatients receiving anticoagulation treatment are allowed to participate with international normalized ratio (INR) established within the therapeutic rangeXx_NEWLINE_xXProthrombin time (PT)-international normalized ratio (INR) =< 2.3 or PT =< 6 seconds above controlXx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); only required for patients receiving anticoagulant therapy; patients are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) must be =< 1.5 unless on therapeutic blood thinnersXx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0 (unless due to therapeutic warfarin use)Xx_NEWLINE_xXInternational normalized ratio or INR must be =< 1.5 unless on therapeutic blood thinnersXx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXConcurrent treatment with warfarin (Coumadin) is allowed, but close monitoring of the prothrombin time (PT)/international normalized ratio (INR) is recommendedXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 2.5Xx_NEWLINE_xXObtained within 2 weeks from study entry: International normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) >= 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 unless using warfarin for therapeutic anti-coagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 x institutional upper limit of normal (IULN); patients receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.4Xx_NEWLINE_xXInternational normalized ratio (INR) > 1.5; (in patients receiving anticoagulants [such as warfarin] INR must be between 2.0 and 3.0 in two consecutive measurements 1-4 days apart)Xx_NEWLINE_xXElevated international normalized ratio (INR) (> 1.7)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXMaximum Child-Pugh score of 5 (NOTE: this requires prothrombin time [PT] or international normalized ratio [INR] measurement at baseline)Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their international normalized ratio (INR) is within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; patients are eligible if elevated INR is due to anti-coagulation medications and will need to provide documentation of stable coagulation parameters prior to study entryXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5; subjects on anticoagulant (such as Coumadin) will be permitted to enroll as long as the INR is in the acceptable therapeutic range as determined by the investigatorXx_NEWLINE_xXProthrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for the management of venous thrombosis including pulmonary embolus)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXPatients on stable anticoagulation are eligible for enrollment; for patients on warfarin, prothrombin time (PT)/international normalized ratio (INR) should be monitored every 2 weeks during induction therapy, monthly thereafter, or more frequent as clinically indicatedXx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 patients receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 (anticoagulation is allowed if target INR =< 1.5 on a stable dose for > 2 weeks at time of study entry)Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.5 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarinXx_NEWLINE_xXEXPANSION COHORT ONLY: Prothrombin time (PT) or international normalized ratio (INR) =< 2 X institutional upper limit of normal (ULN) unless patients are on therapeutic anticoagulation with warfarinXx_NEWLINE_xXInternational normalized ratio (INR) 0.8 to upper limit of normal (ULN) or ? 3 for subjects receiving anticoagulant therapy such as Coumadin or heparinXx_NEWLINE_xXINR < 1.5 × ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.7 (if not due to anticoagulants)Xx_NEWLINE_xXProthrombin time or international normalized ratio (INR) =< 1.5 x upper limit of normal (ULN) unless receiving therapeutic anticoagulationXx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.4 x ULN at the time of registrationXx_NEWLINE_xXPlatelet count <50,000/mm3 or international normalized ratio >1.5.Xx_NEWLINE_xXInternational Normalized Ratio of at least 1.7 Adequate hepatic function including:Xx_NEWLINE_xXPartial thromboplastin time (PTT) must be =< 2 X upper normal limit of institution's normal range and INR (international normalized ratio) < 2; subjects on anticoagulant (such as Coumadin) must have a PTT =< 5 X upper normal limit of institution's normal range and INR (international normalized ratio) < 5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) ? 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) ? 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xX“International normalized ratio” or INR must be =< 1.5Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5Xx_NEWLINE_xXOngoing treatment with warfarin unless the international normalized ratio (INR) is well controlled and below 4Xx_NEWLINE_xXPatients must be appropriate candidates for RFA, with an international normalized ratio of 1.5Xx_NEWLINE_xXINR > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x upper limit of normal unless patient is receiving anticoagulants; if patient is on anticoagulation therapy, levels should be within therapeutic rangeXx_NEWLINE_xXPatient has acceptable coagulation status; for patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time =< 1.3Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXFor patients not receiving anticoagulation: international normalized ratio of a measure of prothrombin time (international normalized ratio [INR]) =< 1.3Xx_NEWLINE_xXInternational Normalized Ratio (INR) < 1.5 and aPTT within 1.1 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) >1.5x ULNXx_NEWLINE_xXInternational normalized ratio (INR) >2.3 or prothrombin time (PT) >6 seconds above controlXx_NEWLINE_xXAdequate coagulation parameters, defined as international normalization ratio (INR) ?Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5Xx_NEWLINE_xXTPI 287 may interfere with coumadin dosing and patients who are taking this combination will require monitoring of their PT, PTT and international normalized ratio (INR).Xx_NEWLINE_xXInternational normalized ratio (INR) greater than 1.3Xx_NEWLINE_xXInternational Normalized Ratio (INR) ?1.7Xx_NEWLINE_xXVitamin K antagonist therapy and an international normalized ratio >1.3 on the day of surgery.Xx_NEWLINE_xXAn abnormal INR (international normalized ratio of greater than 1.3), if repeatable and refractory to correction by routine methodsXx_NEWLINE_xXInternational normalized ratio (INR) >= 1.5Xx_NEWLINE_xXCoagulation: International Normalized Ratio (INR) ? 1.2Xx_NEWLINE_xXInternational normalized ratio (INR) </=1.5 times ULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 or patient off Coumadin at the time of ablationXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5; if on anticoagulation: INR is required to be between 2 and 3Xx_NEWLINE_xXINR ? 1,5Xx_NEWLINE_xXKnown coagulopathy (international normalized ratio [INR] > 1.5, platelets < 75 K)Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 × ULNXx_NEWLINE_xXProthrombin time (PT) with international normalized ratio (INR) ?1.5Xx_NEWLINE_xXInternational normalized ratio (INR) > 2.5 and/orXx_NEWLINE_xXInternational normalized ratio (INR) less than or equal to (?) 1.6 (unless receiving anticoagulation therapy)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or ? 3.0 if on therapeutic anticoagulation)Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 on anticoagulants)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULN; patients receiving anti-coagulation therapy are permitted as long as they have a stable INR =< 3.0Xx_NEWLINE_xXProthrombin time/international normalized ratio (PT INR) < 1.4Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 orXx_NEWLINE_xXProthrombin time (PT) such that international normalized ratio (INR) is =< 1.5 (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin for management of venous thrombosis including pulmonary thromboembolism)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.2 X upper limit of normal (ULN)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.3 (or =< 3 on anticoagulants)Xx_NEWLINE_xXEvidence of active bleeding, a bleeding diathesis or prothrombin time (PT) international normalized ratio (INR) > 1.5Xx_NEWLINE_xXProthrombin time International Normalized Ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5Xx_NEWLINE_xXProthrombin time (PT)/international normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2.0Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 x ULN unless patients are receiving anti-coagulation therapy; patients receiving anti-coagulation therapy with an agent such as warfarin or heparin are allowed to participate if INR =< 3.0Xx_NEWLINE_xXInternational normalized ratio (INR) > 2Xx_NEWLINE_xXSevere hepatic dysfunction accompanied by coagulopathy definition:\r\n* Known liver disease AND\r\n* International normalized ratio (INR) > 1.5 (except for patients on anticoagulants) AND\r\n* Platelet count < 100,000/uL without other obvious causeXx_NEWLINE_xXProthrombin time (PT) and/or international normalized ratio (INR) ? 1.3 × the upper limit of normal (ULN)Xx_NEWLINE_xXWithin 30 days of surgery: International normalized ratio (INR) =< 1.5Xx_NEWLINE_xXPatients with history of severe liver disease, defined as and confirmed by international normalized ratio (INR) 1.5 or greater per institutional laboratory.Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 if on anticoagulant therapy).Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 (corrected if needed)Xx_NEWLINE_xXCurrently on warfarin with an international normalized ratio (INR) > 1.4 or clopidogrel that cannot be discontinued 7 days prior to surgeryXx_NEWLINE_xXInternational normalized ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.8 times institutional upper limit of normalXx_NEWLINE_xXProthrombin time (PT) such that international normalized ratio (INR) is < 1.5 x ULN (or an in-range INR, usually between 2 and 3, if a patient is on a stable dose of therapeutic warfarin)Xx_NEWLINE_xXAbnormal coagulation parameters (international normalized ratio [INR] > 1.5 not on Coumadin, or platelet count < 100,000)Xx_NEWLINE_xXCoagulopathy (international normalized ratio [INR] > 2, platelets < 50,000)Xx_NEWLINE_xXObtained =< 30 days prior to randomization: International normalized ratio (INR) =< 1.6 (if not taking anticoagulant therapy)Xx_NEWLINE_xXAn international normalized ratio (INR) =< 1.5 (patients who are therapeutically anticoagulated for unrelated medical conditions such as atrial fibrillation and whose antithrombotic treatment can be withheld for operation will be eligible)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXPatients with international normalized ratio (INR) > 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXMinocycline trial only: patients who are under treatment of warfarin with international normalized ratio (INR) > 1.5Xx_NEWLINE_xXINR (International Normalized Ratio) <1.5 within 6 weeks screeningXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 (within 30 days of surgery)Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5Xx_NEWLINE_xXInternational normalized ratio (INR) or prothrombin time (PT) within normal institutional limitsXx_NEWLINE_xXSubjects with coagulopathies, including thrombocytopenia with platelet count < 75,000, international normalized ratio (INR) > 1.5 and partial thromboplastin time > 50 secXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXObtained within 28 days prior to registration: International normalized ratio (INR) or prothrombin time (PT) =< 1.5 x ULN (unless on prophylactic or therapeutic dosing with low molecular weight heparin)Xx_NEWLINE_xXInternational normalized ratio (INR) and activated thromboplastin time within normal institutional limitsXx_NEWLINE_xXInternational normalized ratio (INR) =< 2Xx_NEWLINE_xXInternational normalized ratio (INR) =< 1.5 x ULNXx_NEWLINE_xXInternational normalized ratio (INR) =< 1.3Xx_NEWLINE_xXPatients should have international normalized ratio (INR) =< 1.4 and prothrombin time (PT) =< 40 seconds (unless due to lupus anticoagulant); in patients not meeting these parameters, clearance by hematology will be required prior to undergoing a biopsyXx_NEWLINE_xXInternational normalized ratio (INR) < 1.5 \r\n* For patients on Coumadin general clinical guidelines for interventional radiology (IR) ablation will be followedXx_NEWLINE_xXProthrombin time (PT) or international normalized ratio (INR) =< 1.2 X upper limit of normal (ULN) (evaluated within 28 days of randomization); subjects receiving anticoagulant therapy are eligible if their INR is stable and within the recommended range for the desired level of anticoagulationXx_NEWLINE_xXCoagulopathy with international normalized ratio (INR) > 2.0 orXx_NEWLINE_xXSevere coagulopathy (international normalized ratio [INR] > 1.8) orXx_NEWLINE_xXComplete blood count (CBC), chemistry panel (CMP) and coagulation panel (prothrombin time [PT] & international normalized ratio [INR]) no greater than 4 weeks prior to registrationXx_NEWLINE_xXAdequate blood coagulation as evidenced by an International Normalized Ratio (INR) ?1.5.Xx_NEWLINE_xXLow-density lipoprotein (LDL) question for lung surgery do we need an international normalized ratio (INR) < 1.6Xx_NEWLINE_xXInternational normalized ratio (INR) < 1.3 (or < 3 if on warfarin or other anticoagulants) at the screening visitXx_NEWLINE_xXInternational Normalized Ratio (INR) < 1.5 (except if patient is on oral anticoagulation therapy).Xx_NEWLINE_xXInternational Normalized Ratio (INR) >1.5 x ULNXx_NEWLINE_xXAdequate blood coagulation function as evidenced by an International Normalized Ratio (INR) ?1.5.Xx_NEWLINE_xX